{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:07:37Z","timestamp":1794546457692,"version":"4.9.1"},"reference-count":64,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Gene Therapies, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2021,10,3]]},"DOI":"10.1080\/03007995.2021.1947216","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T10:01:40Z","timestamp":1625738500000},"page":"1719-1730","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1"],"prefix":"10.1080","volume":"37","author":[{"given":"Matthias","family":"Bischof","sequence":"first","affiliation":[{"name":"Novartis Gene Therapies, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"Precision HEOR, Oakland, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lee","sequence":"additional","affiliation":[{"name":"Decision Resources Group, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Druyts","sequence":"additional","affiliation":[{"name":"Pharmalytics Group, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakrapani","family":"Balijepalli","sequence":"additional","affiliation":[{"name":"Pharmalytics Group, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Dabbous","sequence":"additional","affiliation":[{"name":"Global Geneconomics and Outcomes Research, Novartis Gene Therapies, Inc, Bannockburn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2010.54"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072222"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90460-3"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.134"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-014-0293-y"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24497"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201288"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000741"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01356-1"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-102319-103602"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.11.6307"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.01.003"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01667-3"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"CIT0019","unstructured":"US Food & Drug Administration. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease#:\u223c:text=The%20U.S.%20Food%20and%20Drug,genetic%20cause%20of%20infant%20mortality"},{"key":"CIT0020","unstructured":"European Medicines Agency. Zolgensma. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma#authorisation-details-section"},{"key":"CIT0021","unstructured":"US Food & Drug Administration. FDA approves first drug for spinal muscular atrophy. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-spinal-muscular-atrophy#:\u223c:text=The%20U.S.%20Food%20and%20Drug,affecting%20muscle%20strength%20and%20movement"},{"key":"CIT0022","unstructured":"European Medicines Agency. Spinraza. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza"},{"key":"CIT0023","unstructured":"US Food & Drug Administration. FDA approves first oral drug treatment for spinal muscular atrophy. Available from: https:\/\/www.news-medical.net\/news\/20200807\/FDA-approves-first-oral-drug-for-treatment-of-spinal-muscular-atrophy.aspx"},{"issue":"1","key":"CIT0024","first-page":"3","volume":"3","author":"Stavarachi M","year":"2010","journal-title":"J Med Life"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190424"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1941310"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01559-4"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1177\/1756285618754459"},{"key":"CIT0030","unstructured":"Evrysdi. Evrysdi prescribing information. 2021. Available from: https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf"},{"key":"CIT0031","unstructured":"European Medicines Agency. Evrysdi. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"CIT0034","first-page":"30280","volume":"19","author":"Lowes L","year":"2019","journal-title":"Pediatr Neurol"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190403"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002445"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.06.198"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.514"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1177\/2633105520973985"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11020194"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0271-1"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.03.1723"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462319000333"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"15","key":"CIT0053","doi-asserted-by":"crossref","first-page":"S25.004","DOI":"10.1212\/WNL.92.15_supplement.S25.004","volume":"92","author":"Finkel R","year":"2019","journal-title":"Neurology"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1097\/PEP.0b013e3182351f04"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123842"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190465"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006050"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27187"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007527"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00923-8"},{"key":"CIT0061","unstructured":"Welton NJ, Phillippo DM, Owen R, et\u00a0al. CHTE2020 sources and synthesis of evidence: update to evidence synthesis methods. March 2020. Available from: CHTE-2020_final_20April2020_final.pdf(nicedsu.org.uk)"},{"key":"CIT0062","doi-asserted-by":"crossref","unstructured":"Daigl M, Kotzeva A, Gorni K, et\u00a0al. How does risdiplam compare in infantile-onset spinal muscular atrophy (SMA)? Preliminary indirect treatment comparisons based on FIREFISH part 1 data. Poster presented at ISPOR Europe; 2019 Nov 2\u20136; Copenhagen, Denmark.","DOI":"10.1016\/j.jval.2019.09.2344"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.1845"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2021.1947216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T17:58:29Z","timestamp":1725386309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2021.1947216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,3]]}},"alternative-id":["10.1080\/03007995.2021.1947216"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2021.1947216","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}